Home › Trials › NCT07177352

Screening to identify people who may qualify for Alzheimer's disease clinical programs

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

Phase 3 Interventional Hoffmann-La Roche · NCT07177352

This screening process tries to find people with recent memory concerns, mild cognitive impairment, or early Alzheimer's who may be eligible for Roche interventional Alzheimer's trials.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment13000 (estimated)
Ages50 Years to 90 Years
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Locations211 sites (Birmingham, Alabama and 210 other locations)
Trial IDNCT07177352 on ClinicalTrials.gov

What this trial studies

This is a pre‑screening process used to determine who might qualify for Roche-sponsored Phase 3 interventional Alzheimer's disease trials. Potential participants provide recent memory complaint history and informant reports and typically complete brief cognitive testing and a medical history review. The process excludes people who are dependent in basic activities of daily living due to cognitive impairment, have other neurologic disorders that could explain cognitive decline, severe CNS trauma, or other serious medical conditions, and accommodates eyeglasses and hearing aids for testing. Pre‑screening is performed at participating clinical sites to create a pool of candidates for subsequent interventional studies.

Who should consider this trial

Good fit: Adults with objective or subjective memory concerns within the past year, including those with mild cognitive impairment or mild dementia due to Alzheimer's, who remain independent in basic daily activities and can complete brief cognitive assessments are ideal candidates.

Not a fit: People who are dependent in basic activities of daily living from cognitive impairment, have other known neurological diseases that explain cognitive problems, severe sensory deficits preventing testing, recent severe CNS trauma, or serious medical conditions are unlikely to benefit from this screening.

Why it matters

Potential benefit: If successful, this screening could speed matching people to appropriate Phase 3 Alzheimer's trials and increase access to potential treatments sooner.

How similar studies have performed: Pre‑screening and registry approaches have been widely used and shown to improve recruitment efficiency for Alzheimer's interventional trials, although patient benefit depends on the outcomes of the subsequent treatment studies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

\- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion Criteria:

* Dependency in basic activities of daily living (bADLs) due to cognitive impairment
* Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
* Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
* History of severe, clinically significant central nervous system trauma
* Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Where this trial is running

Birmingham, Alabama and 210 other locations

+161 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Alzheimers DiseaseEarly Alzheimers DiseaseMild Cognitive ImpairmentMild Dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.